IP Library › Granted Patent US 11,241,441
Granted Patent B2
US 11,241,441 · App. 16/620,144 · Granted Feb 8, 2022

Formulations of lixivaptan for the treatment of polycystic disease

Inventor: Lorenzo Pellegrini (Newtown, PA)
Assignee: PALLADIO BIOSCIENCES, INC.
A61K31/5517A61P13/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,241,441
App. No.
16/620,144
Granted
Feb 8, 2022
Kind
B2
Abstract

Formulations of lixivaptan, and methods of using the same, are provided for the treatment of polycystic disease.

Claims (19)

1. A method of treating autosomal dominant polycystic kidney disease (ADPKD) in a human subject, said method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising lixivaptan and a pharmaceutically acceptable carrier in a divided dose regimen, wherein a total daily dose of lixivaptan is between about 200 mg and about 500 mg.

2. The method of claim 1 , wherein the divided dose regimen consists of a first dose and a second dose.

3. The method of claim 2 , wherein the first dose is between 125 mg and 325 mg lixivaptan.

4. The method of claim 2 , wherein the second dose is between 75 mg and 175 mg lixivaptan.

5. The method of claim 2 , wherein the first dose is 200 mg lixivaptan.

6. The method of claim 2 , wherein the second dose is 100 mg lixivaptan.

7. The method of claim 2 , wherein the second dose is administered about eight hours after the first dose.

8. The method of claim 2 , wherein the second dose is administered about ten hours after the first dose.

9. The method of claim 2 , wherein the second dose is administered about twelve hours after the first dose.

10. The method of claim 2 , wherein the first dose is administered in the morning.

11. The method of claim 2 , wherein the second dose is administered in the evening.

12. The method of claim 1 , wherein the composition is administered for at least one week.

13. The method of claim 1 , wherein the composition is administered for at least two weeks.

14. The method of claim 1 , wherein the composition is administered for at least one month.

15. The method of claim 2 , wherein the first dose is between about 75 mg and about 225 mg lixivaptan.

16. The method of claim 2 , wherein the second dose is between about 75 mg and about 225 mg lixivaptan.

17. The method of claim 2 , wherein the first dose is about 100 mg lixivaptan, and the second dose is about 100 mg lixivaptan.

18. The method of claim 2 , wherein the first dose is about 150 mg lixivaptan, and the second dose is about 150 mg lixivaptan.

19. The method of claim 2 , wherein the first dose is about 200 mg lixivaptan, and the second dose is about 200 mg lixivaptan.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Dec 30, 2024
From: COCOON SA LLC
To: CARDIOKINE BIOPHARMA LLC; CENTESSA BIOSCIENCES, INC.; APCINTEX LIMITED; Z FACTOR LIMITED
Reel/Frame 069702/0875 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2023
From: PALLADIO BIOSCIENCES, INC.
To: CENTESSA BIOSCIENCES, INC.
Reel/Frame 065281/0807 →
SECURITY INTEREST Recorded Oct 4, 2021
From: APCINTEX LIMITED; JANPIX LIMITED; CAPELLA BIOSCIENCE LTD; LOCKBODY THERAPEUTICS LTD; ULTRAHUMAN TWO LIMITED; ULTRAHUMAN FOUR LIMITED; MORPHOGEN-IX LIMITED; OREXIA THERAPEUTICS LIMITED; CARDIOKINE BIOPHARMA LLC; PALLADIO BIOSCIENCES, INC.; PEARLRIVER BIO GMBH; Z FACTOR LIMITED
To: COCOON SA LLC
Reel/Frame 057710/0082 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2021
From: PELLEGRINI, LORENZO
To: PALLADIO BIOSCIENCES, INC.
Reel/Frame 056367/0214 →